Active, not recruitingPhase 2NCT05907954

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Studying Uveal melanoma

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: IDEAYA Biosciences
Principal Investigator: Jasgit Sachdev, MD
IDEAYA Biosciences
Intervention: Darovasertib(drug)
Enrollment: 160 enrolled
Eligibility: 18 years · All sexes
Timeline: 2023 – 2030

Study locations (18)

HonorHealth Research Institute, Scottsdale, Arizona, United States
Moores Cancer Center, La Jolla, California, United States
Stanford Cancer Institute, Palo Alto, California, United States
University of Miami, Miami, Florida, United States
The Cancer and Hematology Centers, Grand Rapids, Michigan, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Northwell, Manhasset, New York, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
St. Vincent's Health Sydney, Sydney, New South Wales, Australia
Alfred Health, Melbourne, Victoria, Australia
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Institute Curie, Paris, France
Charité - Universitätsmedizin Berlin, Berlin, Germany
+3 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05907954 on ClinicalTrials.gov

Other trials for Uveal melanoma

Additional recruiting or active studies for the same condition.

See all trials for Uveal melanoma →

← Back to all trials